162 related articles for article (PubMed ID: 3084749)
1. Immunologic aspects of surface infections in the lung.
Piedra P; Ogra PL
J Pediatr; 1986 May; 108(5 Pt 2):817-23. PubMed ID: 3084749
[TBL] [Abstract][Full Text] [Related]
2. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
3. Harnessing Neutrophil Survival Mechanisms during Chronic Infection by
Marteyn BS; Burgel PR; Meijer L; Witko-Sarsat V
Front Cell Infect Microbiol; 2017; 7():243. PubMed ID: 28713772
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic mechanisms of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients.
Høiby N; Döring G; Schiøtz PO
Antibiot Chemother (1971); 1987; 39():60-76. PubMed ID: 3118792
[No Abstract] [Full Text] [Related]
5. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.
Pier GB
J Infect Dis; 1985 Apr; 151(4):575-80. PubMed ID: 3919113
[No Abstract] [Full Text] [Related]
6. Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.
Fick RB; Olchowski J; Squier SU; Merrill WW; Reynolds HY
Am Rev Respir Dis; 1986 Mar; 133(3):418-22. PubMed ID: 3082264
[TBL] [Abstract][Full Text] [Related]
7. Host defenses in patients with cystic fibrosis: modulation by Pseudomonas aeruginosa.
Speert DP
Surv Synth Pathol Res; 1985; 4(1):14-33. PubMed ID: 3927464
[No Abstract] [Full Text] [Related]
8. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
9. Immunologic aspects of cystic fibrosis.
Döring G; Albus A; Høiby N
Chest; 1988 Aug; 94(2 Suppl):109S-115S. PubMed ID: 3135159
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils Kill Reactive Oxygen Species-Resistant Pseudomonas aeruginosa by Sphingosine.
Becker KA; Li X; Seitz A; Steinmann J; Koch A; Schuchman E; Kamler M; Edwards MJ; Caldwell CC; Gulbins E
Cell Physiol Biochem; 2017; 43(4):1603-1616. PubMed ID: 29040968
[TBL] [Abstract][Full Text] [Related]
11. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Lang AB; Schaad UB; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Cryz SJ
J Pediatr; 1995 Nov; 127(5):711-7. PubMed ID: 7472821
[TBL] [Abstract][Full Text] [Related]
12. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.
Fick RB; Naegel GP; Squier SU; Wood RE; Gee JB; Reynolds HY
J Clin Invest; 1984 Jul; 74(1):236-48. PubMed ID: 6429195
[TBL] [Abstract][Full Text] [Related]
13. Correlation between specific IgG subclass antibodies to Pseudomonas aeruginosa and opsonic activity in serum from patients with cystic fibrosis.
Pressler T; Jensen ET; Espersen F; Pedersen SS; Høiby N; Koch C
Pediatr Pulmonol; 1994 Jan; 17(1):31-40. PubMed ID: 8108174
[TBL] [Abstract][Full Text] [Related]
14. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
Fick RB; Sonoda F; Hornick DB
Semin Respir Infect; 1992 Sep; 7(3):168-78. PubMed ID: 1475541
[TBL] [Abstract][Full Text] [Related]
15. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.
Hornick DB; Fick RB
J Clin Invest; 1990 Oct; 86(4):1285-92. PubMed ID: 2120286
[TBL] [Abstract][Full Text] [Related]
16. Clinical Isolates of Pseudomonas aeruginosa from Chronically Infected Cystic Fibrosis Patients Fail To Activate the Inflammasome during Both Stable Infection and Pulmonary Exacerbation.
Huus KE; Joseph J; Zhang L; Wong A; Aaron SD; Mah TF; Sad S
J Immunol; 2016 Apr; 196(7):3097-108. PubMed ID: 26895832
[TBL] [Abstract][Full Text] [Related]
17. Vaccine strategies against Pseudomonas aeruginosa infection in the lung.
Cripps AW; Dunkley ML; Clancy RL; Kyd J
Behring Inst Mitt; 1997 Feb; (98):262-8. PubMed ID: 9382749
[TBL] [Abstract][Full Text] [Related]
18. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
[TBL] [Abstract][Full Text] [Related]
19. Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.
Kubesch P; Lingner M; Grothues D; Wehsling M; Tümmler B
Scand J Gastroenterol Suppl; 1988; 143():77-80. PubMed ID: 3133755
[TBL] [Abstract][Full Text] [Related]
20. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
